Systemic Lupus Erythematosus | Pharmacor | G7 | 2014

Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development and regulatory hurdles, a small and heterogeneous population, and a multiplicity of manifestations. Recent positive clinical trial results and the regulatory approval of belimumab (GlaxoSmithKline’s Benlysta)—the first new agent in 50 years—have lowered some development hurdles, and a growing list of emerging agents has ushered in a new era of SLE drug development. We forecast that sales of SLE therapies will increase approximately threefold during our 2013-2023 forecast period, driven largely by the entry and uptake of premium-priced biologics.

Login to access report

launch Related Market Assessment Reports